AstraZeneca PLC is returning to the interleukin-23 space after recovering all the rights to the inflammatory bowel disease drug brazikumab from Allergan PLC which has been divested to avoid antitrust issues ahead of the latter's takeover by AbbVie Inc..
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?